Gapping down
In reaction to disappointing earnings/guidance: WYNN -9.2%, EXAC -6.8%, MAT -2.4%, SYRG -1.9%, GE -1.5%, SLB -0.7%, AMD -0.5% (also signs JV with Nantong Fujitsu Microelectronics, who is paying AMD $371 mln).
WYNN casino / gaming peers are under pressure: LVS -2.9%, MGM -2.9%, MPEL -2.5%.
Select metals/mining stocks trading lower: VALE -1.2% (announces on its website that its Board approved the payment of the second installment of the 2015 dividends of $500 mln, or ~$0.097 per share),RIO -1% (reports Q3 production, global iron ore shipments were +17% y/y), ABX -1%, SLV -0.8%, GDX -0.7%, GLD -0.3%.
WYNN casino / gaming peers are under pressure: LVS -2.9%, MGM -2.9%, MPEL -2.5%.
Select metals/mining stocks trading lower: VALE -1.2% (announces on its website that its Board approved the payment of the second installment of the 2015 dividends of $500 mln, or ~$0.097 per share),RIO -1% (reports Q3 production, global iron ore shipments were +17% y/y), ABX -1%, SLV -0.8%, GDX -0.7%, GLD -0.3%.
Other news: ZFGN -28.6% (receives verbal notice from the FDA that beloranib has been placed on partial clinical hold; patient who died was receiving beloranib), CRZO -5.4% (announces estimated q3 production and raises 2015 crude oil production growth target; Estimated Q3 crude oil production of 23,573 Bbls/d, 4% above the high-end of the guidance range; announces public offering of 5.3 mln shares of common stock; prices the upsized offer of 5.5 mln shares of its common stock for gross proceeds of ~$211.8 mln), MYCC -4% (prices secondary offering of 8,968,922 shares at $20.80 per share), SAVE -3.8% (reaffirms prior Q3 revenue guidance, increases operating margin guidance; however, prices are low, capacity growth in 2016 now expected at lower end of prior guidance range; downgraded to Equal-Weight from Overweight at Morgan Stanley), SLRC -3.7% (Solar Capital reports that Voya Financial has agreed to invest in its Senior Secured Unitranche Loan Program), RDUS -2.4% (up ~20% yesterday on Shire M&A speculation), AZN -1.9% (receives a Complete Response Letter from the FDA regarding the NDA for the investigational fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adult patients with type 2 diabetes), JAH -0.7% (prices the underwritten public offering of 10 mln shares of its common stock at $49.00/share).
Analyst comments: NAV -4.2% (downgraded to Neutral from Buy at Longbow)
Analyst comments: NAV -4.2% (downgraded to Neutral from Buy at Longbow)